BG108534A - Фотосенсибилизатор и метод за неговото получаване - Google Patents

Фотосенсибилизатор и метод за неговото получаване Download PDF

Info

Publication number: BG108534A
Authority: BG; Bulgaria
Prior art keywords: chlorine; solution; photosensitizer; added; extract
Prior art date: 2001-03-30

Application number

BG108534A

Other languages

Bulgarian (bg)

English (en)

Inventor

Andrei Reshetnikov

Igor Zalevsky

Jury Kemov

Andrei IVANOV

Artashes Karmenyan

Alexandr Gradjushko

Vladimir Laptev

Nataliya Neugodova

Olga Abakumova

Valery Privalov

Alexandr LAPPA

Vladimir Romanov

Original Assignee

Obschestvo S Ogranichennoi Otvetstvennostiju "Rada-Pharma"

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-30

Filing date

2004-01-16

Publication date

2005-02-28

2004-01-16 Application filed by Obschestvo S Ogranichennoi Otvetstvennostiju "Rada-Pharma" filed Critical Obschestvo S Ogranichennoi Otvetstvennostiju "Rada-Pharma"

2005-02-28 Publication of BG108534A publication Critical patent/BG108534A/bg

Links

238000004519 manufacturing process Methods 0.000 title claims description 7
BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 claims abstract description 96
239000000460 chlorine Substances 0.000 claims abstract description 89
229910052801 chlorine Inorganic materials 0.000 claims abstract description 89
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 84
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 83
239000000203 mixture Substances 0.000 claims abstract description 55
239000002585 base Substances 0.000 claims abstract description 29
239000002028 Biomass Substances 0.000 claims abstract description 16
229910052783 alkali metal Inorganic materials 0.000 claims abstract description 7
235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 5
240000002900 Arthrospira platensis Species 0.000 claims abstract description 5
229940082787 spirulina Drugs 0.000 claims abstract description 5
150000001340 alkali metals Chemical class 0.000 claims abstract description 4
230000007062 hydrolysis Effects 0.000 claims abstract description 3
238000006460 hydrolysis reaction Methods 0.000 claims abstract description 3
239000000243 solution Substances 0.000 claims description 99
239000000284 extract Substances 0.000 claims description 65
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 63
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 54
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
238000000034 method Methods 0.000 claims description 43
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 38
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 34
239000003504 photosensitizing agent Substances 0.000 claims description 33
239000002244 precipitate Substances 0.000 claims description 30
238000006243 chemical reaction Methods 0.000 claims description 27
239000008215 water for injection Substances 0.000 claims description 19
239000007788 liquid Substances 0.000 claims description 18
239000007864 aqueous solution Substances 0.000 claims description 17
238000001914 filtration Methods 0.000 claims description 17
CQIKWXUXPNUNDV-AXRVZGOCSA-N pheophytin a Chemical compound N1C(C=C2[C@H]([C@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=N2)C2=C3NC(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C=C)=C1C=C1C(C)=C(CC)C4=N1 CQIKWXUXPNUNDV-AXRVZGOCSA-N 0.000 claims description 17
238000005119 centrifugation Methods 0.000 claims description 16
SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims description 15
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 13
238000002523 gelfiltration Methods 0.000 claims description 13
229910052500 inorganic mineral Inorganic materials 0.000 claims description 13
239000011707 mineral Substances 0.000 claims description 13
239000008346 aqueous phase Substances 0.000 claims description 11
239000012153 distilled water Substances 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 9
-1 alkali metal salt Chemical class 0.000 claims description 9
229930002875 chlorophyll Natural products 0.000 claims description 7
235000019804 chlorophyll Nutrition 0.000 claims description 7
125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 6
241000894006 Bacteria Species 0.000 claims description 6
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 6
229930002868 chlorophyll a Natural products 0.000 claims description 6
229910001425 magnesium ion Inorganic materials 0.000 claims description 6
239000012074 organic phase Substances 0.000 claims description 6
239000000758 substrate Substances 0.000 claims description 6
239000000654 additive Substances 0.000 claims description 5
125000004185 ester group Chemical group 0.000 claims description 4
SLMWNIYULHWWHD-UHFFFAOYSA-N hexane;propan-2-one;hydrochloride Chemical compound Cl.CC(C)=O.CCCCCC SLMWNIYULHWWHD-UHFFFAOYSA-N 0.000 claims description 4
OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 claims description 4
238000011084 recovery Methods 0.000 claims description 4
239000001509 sodium citrate Substances 0.000 claims description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
150000004035 chlorins Chemical class 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
239000000470 constituent Substances 0.000 claims description 2
239000011591 potassium Substances 0.000 claims description 2
229910052700 potassium Inorganic materials 0.000 claims description 2
238000001556 precipitation Methods 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
HWOYUZFPNXLWQP-UHFFFAOYSA-N Cc1c2ccc(n2)c(C)c2ccc([nH]2)c(C)c2ccc(n2)c(C)c2ccc1[nH]2 Chemical compound Cc1c2ccc(n2)c(C)c2ccc([nH]2)c(C)c2ccc(n2)c(C)c2ccc1[nH]2 HWOYUZFPNXLWQP-UHFFFAOYSA-N 0.000 claims 1
NSFSLUUZQIAOOX-LDCXZXNSSA-N pheophorbide a Chemical class N1C(C=C2[C@H]([C@H](CCC(O)=O)C(=N2)C2=C3NC(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C=C)=C1C=C1C(C)=C(CC)C4=N1 NSFSLUUZQIAOOX-LDCXZXNSSA-N 0.000 claims 1
150000004032 porphyrins Chemical class 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 43
239000003814 drug Substances 0.000 abstract description 7
OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 abstract description 3
150000003839 salts Chemical class 0.000 abstract description 3
238000004090 dissolution Methods 0.000 abstract description 2
238000000605 extraction Methods 0.000 abstract description 2
COWCVGUYIYQWPC-MRZQNBKKSA-N purpurin 18 Chemical compound N1C(C=C2C(=C(CC)C(C=C3C(=C4C(=C5C(=O)OC4=O)N3)C)=N2)C)=C(C=C)C(C)=C1C=C1C(C)C(CCC(=O)OCC(/C)=C/CCC(C)CCCC(C)CCCC(C)CC)C5=N1 COWCVGUYIYQWPC-MRZQNBKKSA-N 0.000 abstract description 2
238000006386 neutralization reaction Methods 0.000 abstract 2
238000010306 acid treatment Methods 0.000 abstract 1
238000001226 reprecipitation Methods 0.000 abstract 1
235000017168 chlorine Nutrition 0.000 description 81
239000000126 substance Substances 0.000 description 47
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
238000002360 preparation method Methods 0.000 description 39
210000004027 cell Anatomy 0.000 description 27
238000001228 spectrum Methods 0.000 description 27
239000000499 gel Substances 0.000 description 26
238000002347 injection Methods 0.000 description 26
239000007924 injection Substances 0.000 description 26
235000019441 ethanol Nutrition 0.000 description 21
238000002428 photodynamic therapy Methods 0.000 description 21
230000000694 effects Effects 0.000 description 17
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 16
239000002552 dosage form Substances 0.000 description 16
210000001519 tissue Anatomy 0.000 description 16
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
238000012360 testing method Methods 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
241000699670 Mus sp. Species 0.000 description 12
230000035508 accumulation Effects 0.000 description 12
238000009825 accumulation Methods 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
150000001875 compounds Chemical class 0.000 description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
238000000862 absorption spectrum Methods 0.000 description 10
210000004369 blood Anatomy 0.000 description 10
239000008280 blood Substances 0.000 description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
238000001819 mass spectrum Methods 0.000 description 10
235000010755 mineral Nutrition 0.000 description 10
230000008569 process Effects 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
206010039509 Scab Diseases 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 9
230000007423 decrease Effects 0.000 description 9
239000000047 product Substances 0.000 description 9
230000006820 DNA synthesis Effects 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
210000003205 muscle Anatomy 0.000 description 8
TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 8
239000008363 phosphate buffer Substances 0.000 description 8
239000000523 sample Substances 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
230000001472 cytotoxic effect Effects 0.000 description 7
210000004185 liver Anatomy 0.000 description 7
230000004071 biological effect Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
239000013078 crystal Substances 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 6
230000006378 damage Effects 0.000 description 6
239000002207 metabolite Substances 0.000 description 6
239000002904 solvent Substances 0.000 description 6
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 6
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 5
206010028851 Necrosis Diseases 0.000 description 5
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
125000004432 carbon atom Chemical group C* 0.000 description 5
238000009826 distribution Methods 0.000 description 5
239000011521 glass Substances 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 5
230000017074 necrotic cell death Effects 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
239000003921 oil Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000000844 anti-bacterial effect Effects 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
125000001309 chloro group Chemical class Cl* 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000002265 electronic spectrum Methods 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
238000002189 fluorescence spectrum Methods 0.000 description 4
230000001738 genotoxic effect Effects 0.000 description 4
239000008240 homogeneous mixture Substances 0.000 description 4
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 4
239000010410 layer Substances 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000012071 phase Substances 0.000 description 4
239000011148 porous material Substances 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
208000020352 skin basal cell carcinoma Diseases 0.000 description 4
210000000813 small intestine Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000036326 tumor accumulation Effects 0.000 description 4
RBPHBLDGMYKMKY-BDVNFPICSA-N (2R,3R,4R,5S)-6-(methoxyamino)hexane-1,2,3,4,5-pentol Chemical compound CONC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO RBPHBLDGMYKMKY-BDVNFPICSA-N 0.000 description 3
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 3
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
238000000134 MTT assay Methods 0.000 description 3
231100000002 MTT assay Toxicity 0.000 description 3
239000006227 byproduct Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001804 chlorine Chemical class 0.000 description 3
239000002537 cosmetic Substances 0.000 description 3
230000034994 death Effects 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
230000029142 excretion Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
231100000025 genetic toxicology Toxicity 0.000 description 3
150000002430 hydrocarbons Chemical group 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
238000000746 purification Methods 0.000 description 3
239000002510 pyrogen Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
IQFYYKKMVGJFEH-OYDXRQHMSA-N 1-[(2r,4s,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H]([14CH2]O)[C@@H](O)C1 IQFYYKKMVGJFEH-OYDXRQHMSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
206010054094 Tumour necrosis Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
230000002380 cytological effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
230000032050 esterification Effects 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
230000005284 excitation Effects 0.000 description 2
239000004744 fabric Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000011835 investigation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
150000002678 macrocyclic compounds Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000005192 partition Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
206010040882 skin lesion Diseases 0.000 description 2
231100000444 skin lesion Toxicity 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
231100000563 toxic property Toxicity 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
238000005303 weighing Methods 0.000 description 2
239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
NZDXSXLYLMHYJA-UHFFFAOYSA-M 4-[(1,3-dimethylimidazol-1-ium-2-yl)diazenyl]-n,n-dimethylaniline;chloride Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1N=NC1=[N+](C)C=CN1C NZDXSXLYLMHYJA-UHFFFAOYSA-M 0.000 description 1
MLNJTSJAWPXDSS-UHFFFAOYSA-N C(=C)C=1C(=C2NC=1C=C1C(=C(C(=N1)C=C1C(=CC(N1)=CC=1C=C(C(N=1)=C2)C)C)CC)C)C Chemical compound C(=C)C=1C(=C2NC=1C=C1C(=C(C(=N1)C=C1C(=CC(N1)=CC=1C=C(C(N=1)=C2)C)C)CC)C)C MLNJTSJAWPXDSS-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000003098 Ganglion Cysts Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
101100067761 Rattus norvegicus Gast gene Proteins 0.000 description 1
101000595041 Rattus norvegicus Podocalyxin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010042618 Surgical procedure repeated Diseases 0.000 description 1
208000005400 Synovial Cyst Diseases 0.000 description 1
HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
231100000605 Toxicity Class Toxicity 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
JNDMLEXHDPKVFC-UHFFFAOYSA-N aluminum;oxygen(2-);yttrium(3+) Chemical compound [O-2].[O-2].[O-2].[Al+3].[Y+3] JNDMLEXHDPKVFC-UHFFFAOYSA-N 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
238000009534 blood test Methods 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
JJBKVCQUFIBRFK-UHFFFAOYSA-N chloromethane;methanol Chemical compound OC.ClC JJBKVCQUFIBRFK-UHFFFAOYSA-N 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
210000000448 cultured tumor cell Anatomy 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical group 0.000 description 1
230000005281 excited state Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
231100000024 genotoxic Toxicity 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
210000004020 intracellular membrane Anatomy 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
LGAILEFNHXWAJP-BMEPFDOTSA-N macrocycle Chemical group N([C@H]1[C@@H](C)CC)C(=O)C(N=2)=CSC=2CNC(=O)C(=C(O2)C)N=C2[C@H]([C@@H](C)CC)NC(=O)C2=CSC1=N2 LGAILEFNHXWAJP-BMEPFDOTSA-N 0.000 description 1
150000002680 magnesium Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
POPDQJMNXQQAII-UWJYYQICSA-N methyl 3-[(22S,23S)-17-ethenyl-12-ethyl-13,18,22,27-tetramethyl-3,5-dioxo-4-oxa-8,24,25,26-tetrazahexacyclo[19.2.1.16,9.111,14.116,19.02,7]heptacosa-1,6,9(27),10,12,14(26),15,17,19(25),20-decaen-23-yl]propanoate Chemical compound CCc1c(C)c2cc3nc(cc4[nH]c([C@@H](CCC(=O)OC)[C@@H]4C)c4c5[nH]c(cc1n2)c(C)c5c(=O)oc4=O)c(C)c3C=C POPDQJMNXQQAII-UWJYYQICSA-N 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000002186 photoactivation Effects 0.000 description 1
230000036211 photosensitivity Effects 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000005086 pumping Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000007142 ring opening reaction Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000012488 sample solution Substances 0.000 description 1
239000004065 semiconductor Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000002002 slurry Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
229910019655 synthetic inorganic crystalline material Inorganic materials 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
229910019901 yttrium aluminum garnet Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)
Light Receiving Elements (AREA)
Steroid Compounds (AREA)

BG108534A 2001-03-30 2004-01-16 Фотосенсибилизатор и метод за неговото получаване BG108534A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
RU2001108397/14A RU2183956C1 (ru)	2001-03-30	2001-03-30	Фотосенсибилизатор и способ его получения

Publications (1)

Publication Number	Publication Date
BG108534A true BG108534A (bg)	2005-02-28

Family

ID=20247772

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108534A BG108534A (bg)	2001-03-30	2004-01-16	Фотосенсибилизатор и метод за неговото получаване

Country Status (23)

Country	Link
US (2)	US6969765B2 (fr)
EP (1)	EP1380295B1 (fr)
KR (1)	KR100628548B1 (fr)
CN (1)	CN1250294C (fr)
AT (1)	ATE426403T1 (fr)
AU (1)	AU2002212867B2 (fr)
BG (1)	BG108534A (fr)
BR (1)	BR0116952A (fr)
CA (1)	CA2440650C (fr)
CZ (1)	CZ304591B6 (fr)
DE (1)	DE60138141D1 (fr)
GB (1)	GB2389531B (fr)
HR (1)	HRP20030876B1 (fr)
HU (1)	HU227756B1 (fr)
MX (1)	MXPA03008925A (fr)
NO (1)	NO327751B1 (fr)
NZ (1)	NZ528237A (fr)
PL (1)	PL206902B1 (fr)
RU (1)	RU2183956C1 (fr)
SI (1)	SI1380295T1 (fr)
SK (1)	SK287784B6 (fr)
WO (1)	WO2002078694A1 (fr)
ZA (1)	ZA200308407B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2228750C1 (ru) *	2002-09-13	2004-05-20	Мещерякова Аделия Леонидовна	Способ получения хлорина е6
RU2228775C1 (ru) *	2002-10-01	2004-05-20	Общество с ограниченной ответственностью "РАДА-ФАРМА"	Способ фотодинамического лечения острого и хронического гнойного гайморита
WO2004110438A1 (fr) *	2003-06-17	2004-12-23	Peter Timofeevich Petrov	Agent de diagnostic et de therapie photodynamiques de maladies oncologiques
RU2244533C1 (ru) *	2003-07-01	2005-01-20	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова	Способ электрохимической деструкции, хирургического удаления и фотодинамической профилактики рецидивов внутриглазных новообразований в среде перфторорганического соединения (варианты)
RU2243755C1 (ru) *	2003-07-01	2005-01-10	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова	Способ хирургической электрохимической деструкции и фотодинамического лечения внутриглазных новообразований
RU2243753C1 (ru) *	2003-07-01	2005-01-10	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова	Способ хирургического фотодинамического лечения хориоидальных гемангиом
RU2244532C1 (ru) *	2003-07-01	2005-01-20	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова	Способ хирургического фотодинамического лечения субретинальных неоваскулярных мембран (варианты)
RU2244531C1 (ru) *	2003-07-01	2005-01-20	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им.акад. С.Н.Федорова	Способ электрохимической деструкции, хирургического удаления и фотодинамической профилактики рецидивов внутриглазных новообразований (варианты)
RU2243748C1 (ru) *	2003-07-01	2005-01-10	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова	Способ хирургического удаления и фотодинамической профилактики рецидивов субретинальных неоваскулярных мембран
CA2437638A1 (fr) *	2003-08-20	2005-02-20	John Robert North	Therapie photodynamique
GB0323358D0 (en) *	2003-10-06	2003-11-05	Green Grass Design Ltd	Novel compounds and processes
RU2256446C1 (ru) *	2003-10-22	2005-07-20	Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова	Способ профилактики метастазов после хирургического удаления внутриглазных новообразований
PL368213A1 (en) *	2004-05-25	2005-11-28	ADAMED Sp.z o.o.	New coupling, method for its fabrication and its application
US8349335B2 (en) *	2006-11-03	2013-01-08	Gwangju Institute Of Science And Technology	Methods for preparing chlorophyll a and chlorin e6
RU2345803C2 (ru) *	2006-11-30	2009-02-10	Закрытое Акционерное Общество "Исследовательские лаборатории "РАДА-ФАРМА"	Способ фотоиммунотерапии фотосенсибилизатором, активируемым волновой энергией вне организма человека
KR100808630B1 (ko) *	2006-12-28	2008-02-29	광주과학기술원	클로린 화합물을 포함하는 경구투여용 항종양 조성물
RU2330037C1 (ru) *	2006-12-28	2008-07-27	Гелий Васильевич Пономарев	СПОСОБ ПОЛУЧЕНИЯ ХЛОРИНА e6
CN100496516C (zh) *	2007-12-03	2009-06-10	贵州圣济堂制药有限公司	一种螺旋藻组合物及其制备方法与应用
RU2367434C1 (ru) *	2008-04-22	2009-09-20	Виктор Александрович Борисов	Фотосенсибилизатор и способ его получения
RU2428175C2 (ru) *	2008-06-02	2011-09-10	Закрытое Акционерное Общество "Биокад"	Способ получения парентерального фармацевтического раствора
KR100896327B1 (ko) *	2008-09-09	2009-05-07	다이아텍코리아 주식회사	스피루리나로부터 클로로필 ａ 및 클로린을 제조하는 방법
KR100918810B1 (ko)	2009-04-29	2009-09-25	다이아텍코리아 주식회사	클로린 ｅ６-엽산 결합 화합물을 함유하는 암 치료용 약학적 조성물
JP2011518890A (ja)	2009-04-29	2011-06-30	ドイアテクフコリアシーオー．，エルティーディー．	新規のクロリンｅ６−葉酸結合化合物、その製造方法、およびそれを含有する癌治療用薬学的組成物
ES2354096B1 (es) *	2009-07-27	2012-02-23	Nuevas Tecnologias Cientificas, S.A.	Procedimiento para la obtencion de un fotosensibilizante para ser empleado en terapia fotodinamica y fotosensibilizante.
KR100950441B1 (ko) *	2009-09-30	2010-04-02	주식회사 아큐텍	스피루리나로부터 클로로필 ａ 및 포토디타진을 제조하는 방법
RU2428981C1 (ru) *	2010-03-31	2011-09-20	Анатолий Юрьевич Барышников	Средство для фотодинамической терапии, способ получения предлагаемого средства и способ проведения фотодинамической терапии с использованием предлагаемого средства
RU2490273C1 (ru) *	2012-02-27	2013-08-20	Оскар Иосифович Койфман	Способ получения метилфеофорбида (а)
PL2931728T3 (pl) *	2012-12-14	2020-11-02	Rmw Cho Group Limited	Pochodna chloryny przydatna w terapii fotodynamicznej i diagnostyce
RU2523380C1 (ru) *	2013-05-21	2014-07-20	Общество с ограниченной ответственностью "ГЕЛИОХЛОРИН"	Фотосенсибилизатор и способ его получения
CN105777760A (zh) *	2014-12-23	2016-07-20	深圳市中兴扬帆生物工程有限公司	四间-羟基苯基二氢卟酚原料药的保存方法
CN106349736A (zh) *	2016-08-05	2017-01-25	雷春生	一种纯有机光敏染料的制备方法
KR102357787B1 (ko) *	2016-12-14	2022-02-03	동성제약주식회사	고순도 트리소듐 클로린 e6(trisodium Chlorin e6)와 PVP (polyvinylpyrrolidone)의 복합체 제조 방법과 Chlorin e6의 제조 방법
RU2670087C1 (ru) *	2018-01-29	2018-10-18	Михаил Александрович Грин	Фотосенсибилизатор для лечения рака предстательной железы и способ его получения
RU2691754C1 (ru) *	2018-11-15	2019-06-18	Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского"	ПРОИЗВОДНОЕ ЦИНКОВОГО МЕТАЛЛОКОМПЛЕКСА ХЛОРИНА-e6 И ЕГО ПРИМЕНЕНИЕ
CN112521392A (zh) *	2019-09-18	2021-03-19	康俄(上海)医疗科技有限公司	一种二氢卟吩e6的纯化方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3102891A (en)	1959-11-16	1963-09-03	Elmer A Allen	New porphyrinic and chlorophyllic compositions and process therefor
US4977177A (en)	1985-04-30	1990-12-11	Nippon Petrochemicals Company, Ltd.	Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents
ATE87826T1 (de) *	1986-01-02	1993-04-15	Univ Toledo	Herstellung und verwendung von purpurinen, chlorinen und purpurin und chlorin enthaltenden zubereitungen.
US5534506A (en) *	1986-01-02	1996-07-09	University Of Toledo	Use of purpurins, chlorins and purpurin- and chlorin-containing compositions
US5216012A (en) *	1986-01-02	1993-06-01	University Of Toledo	Production and use of purpurins, chlorins and purpurin- and chlorin-containing compositions
US5002962A (en)	1988-07-20	1991-03-26	Health Research, Inc.	Photosensitizing agents
JP2963178B2 (ja)	1990-09-27	1999-10-12	株式会社エス・エル・ティ・ジャパン	水溶性フェオホーバイドａの製造方法
US5330741A (en) *	1992-02-24	1994-07-19	The Regents Of The University Of California	Long-wavelength water soluble chlorin photosensitizers useful for photodynamic therapy and diagnosis of tumors
US5807881A (en) *	1992-05-27	1998-09-15	Quadra Logic Technologies, Inc.	Method for selectively reducing activated leukocyte cell population
RU2054476C1 (ru) *	1993-07-14	1996-02-20	Мещерякова Аделия Леонидовна	Способ получения 18-карбокси-20-(карбоксиметил)-8-этенил-13-этил-2,3-дигидро-3,7-12,17-тетраметил-21н, 23нпорфин-2-пропионовой кислоты или ее солей
IL116126A0 (en) *	1995-11-24	1996-01-31	Yeda Res & Dev	Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them
GB9700396D0 (en) *	1997-01-10	1997-02-26	Photocure As	Photochemotherapeutic compositions
RU2152790C1 (ru) *	1999-05-12	2000-07-20	Мещерякова Аделия Леонидовна	Средство для фотодинамической диагностики и терапии онкологических заболеваний

2001
- 2001-03-30 RU RU2001108397/14A patent/RU2183956C1/ru not_active IP Right Cessation
- 2001-10-04 CA CA002440650A patent/CA2440650C/fr not_active Expired - Fee Related
- 2001-10-04 NZ NZ528237A patent/NZ528237A/en not_active IP Right Cessation
- 2001-10-04 CZ CZ2003-2940A patent/CZ304591B6/cs not_active IP Right Cessation
- 2001-10-04 EP EP01981209A patent/EP1380295B1/fr not_active Expired - Lifetime
- 2001-10-04 DE DE60138141T patent/DE60138141D1/de not_active Expired - Lifetime
- 2001-10-04 HR HR20030876A patent/HRP20030876B1/xx not_active IP Right Cessation
- 2001-10-04 HU HU0400298A patent/HU227756B1/hu not_active IP Right Cessation
- 2001-10-04 PL PL365102A patent/PL206902B1/pl unknown
- 2001-10-04 US US10/473,445 patent/US6969765B2/en not_active Expired - Fee Related
- 2001-10-04 SK SK1348-2003A patent/SK287784B6/sk not_active IP Right Cessation
- 2001-10-04 WO PCT/RU2001/000399 patent/WO2002078694A1/fr not_active Ceased
- 2001-10-04 BR BR0116952-1A patent/BR0116952A/pt not_active IP Right Cessation
- 2001-10-04 GB GB0321726A patent/GB2389531B/en not_active Expired - Fee Related
- 2001-10-04 SI SI200130919T patent/SI1380295T1/sl unknown
- 2001-10-04 MX MXPA03008925A patent/MXPA03008925A/es active IP Right Grant
- 2001-10-04 AT AT01981209T patent/ATE426403T1/de not_active IP Right Cessation
- 2001-10-04 AU AU2002212867A patent/AU2002212867B2/en not_active Ceased
- 2001-10-04 KR KR1020037012876A patent/KR100628548B1/ko not_active Expired - Fee Related
- 2001-10-04 CN CNB018230938A patent/CN1250294C/zh not_active Expired - Fee Related
2003
- 2003-09-29 NO NO20034344A patent/NO327751B1/no not_active IP Right Cessation
- 2003-10-29 ZA ZA2003/08407A patent/ZA200308407B/en unknown
2004
- 2004-01-16 BG BG108534A patent/BG108534A/bg unknown
2005
- 2005-06-30 US US11/171,076 patent/US7550587B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
HRP20030876B1 (en)	2011-10-31
CN1250294C (zh)	2006-04-12
CZ20032940A3 (cs)	2004-04-14
HUP0400298A2 (hu)	2004-07-28
HRP20030876A2 (en)	2005-08-31
KR100628548B1 (ko)	2006-09-26
CZ304591B6 (cs)	2014-07-23
GB2389531B (en)	2005-03-16
KR20040025911A (ko)	2004-03-26
EP1380295B1 (fr)	2009-03-25
AU2002212867B2 (en)	2007-07-12
ATE426403T1 (de)	2009-04-15
NZ528237A (en)	2006-09-29
GB0321726D0 (en)	2003-10-15
MXPA03008925A (es)	2005-03-07
SI1380295T1 (sl)	2009-10-31
PL365102A1 (en)	2004-12-27
GB2389531A (en)	2003-12-17
EP1380295A9 (fr)	2004-04-14
BR0116952A (pt)	2004-06-01
CN1512881A (zh)	2004-07-14
US20060003983A1 (en)	2006-01-05
PL206902B1 (pl)	2010-10-29
NO20034344L (no)	2003-11-21
ZA200308407B (en)	2005-02-23
SK13482003A3 (sk)	2004-05-04
SK287784B6 (sk)	2011-09-05
RU2183956C1 (ru)	2002-06-27
NO327751B1 (no)	2009-09-14
US7550587B2 (en)	2009-06-23
EP1380295A4 (fr)	2005-11-30
WO2002078694A1 (fr)	2002-10-10
EP1380295A1 (fr)	2004-01-14
CA2440650C (fr)	2009-09-15
HU227756B1 (en)	2012-02-28
US6969765B2 (en)	2005-11-29
NO20034344D0 (no)	2003-09-29
DE60138141D1 (de)	2009-05-07
US20040147499A1 (en)	2004-07-29
HUP0400298A3 (en)	2007-05-29
CA2440650A1 (fr)	2002-10-10

Publication	Publication Date	Title
RU2183956C1 (ru)	2002-06-27	Фотосенсибилизатор и способ его получения
US9040687B2 (en)	2015-05-26	Process for the preparaton of novel porphyrin derivatives and their use as PDT agents and fluorescence probes
JP6832358B2 (ja)	2021-02-24	５−アミノレブリン酸及び誘導体の塩
JP2016502999A (ja)	2016-02-01	光線力学療法および診断に有用なクロリン誘導体
CN107987081A (zh)	2018-05-04	一种新型二氢卟吩e6衍生物及其药学上可接受的盐、其制备方法和应用
NO334978B1 (no)	2014-08-11	Vannløselig anionisk bakterieklorofyllderivat, fremgangsmåte for fremstilling derav, farmasøytisk sammensetning som inneholder nevnte derivat og anvendelse derav.
JPS625912A (ja)	1987-01-12	新規なテトラピロ−ル医薬用組成物
Xiao et al.	2023	Phycocyanobilin from Arthrospira platensis: A potential photodynamic anticancer agent
CN104844645A (zh)	2015-08-19	一种轴向ala修饰的硅酞菁及其制备方法和应用
CN117126156A (zh)	2023-11-28	一种苯并硒二唑衍生物及其制备方法和应用
CN101518528B (zh)	2014-02-26	一组碳花青染料类的近红外荧光化合物的用途
CN116425732B (zh)	2024-05-31	一种具有线粒体靶向功能的光可控释放no并开启光动力效果的光敏剂及其制备方法和应用
RU2523380C1 (ru)	2014-07-20	Фотосенсибилизатор и способ его получения
JP2004512270A (ja)	2004-04-22	ジヒドロポルフィリンの誘導体とその使用
CN106083872B (zh)	2019-02-19	紫红素-18醚类衍生物及其制备方法和用途
CN108164570A (zh)	2018-06-15	一种含硒光敏剂及其制备方法和应用
Xie et al.	2025	Glycosylated Phosphorous (V) Corrole as effective Photosensitizers for Cancer Photodynamic Therapy via Enhancing cellular Uptake
CN105646493B (zh)	2018-02-02	一种用于预防和治疗器官损伤的化合物及其制备方法和用途
Zhang et al.	2016	In vitro and in vivo antitumor activity of a novel chlorin derivative for photodynamic therapy
CN120309558A (zh)	2025-07-15	一种基于吩噻嗪细胞膜靶向光敏剂及其制备方法和应用
CN100422167C (zh)	2008-10-01	环己酮类饱和双环(桥环)化合物及其制备方法与用途
CN120398932A (zh)	2025-08-01	一种光敏剂、乏氧响应激活式光敏性化合物及其应用
WO2016204060A1 (fr)	2016-12-22	Amplificateur d'effet photodynamique dans le traitement ala-tpd ou le diagnostic ala-dpd